Biotechnology Breakthrough for Asthma
FDA approves Xolair, the first humanized antibody to target IgE, responsible for asthma with an allergic component
24-Jun-2003 -
Genentech, Inc.Novartis Pharmaceuticals Corporation and Tanox, Inc. announced that the novel IgE-blocker Xolair® (Omalizumab) for subcutaneous use has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of moderate-to-severe persistent asthma in adults and adolescents. ...
antibodies
asthma
biotechnology
+11